Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
190 studies found for:    "Nerve sheath neoplasm"
Show Display Options
RSS Create an RSS feed from your search for:
"Nerve sheath neoplasm"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas
Condition: Neurofibroma
Intervention: Drug: LS11
2 Unknown  First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas
Condition: Cutaneous Neurofibromas
Intervention: Procedure: Erbium-YAG laser vaporization
3 Active, not recruiting Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
Conditions: Neurofibromatosis;   Neurofibromas
Intervention: Drug: Gleevec
4 Active, not recruiting Study of PEG-Intron for Plexiform Neurofibromas
Condition: Plexiform Neurofibroma
Intervention: Drug: PEG-Intron
5 Terminated Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
Condition: Malignant Peripheral Nerve Sheath Tumors
Intervention: Drug: imatinib mesylate
6 Recruiting Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
Condition: Plexiform Neurofibromas
Intervention: Drug: Imatinib Mesylate
7 Terminated
Has Results
Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
Condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
Intervention: Drug: Everolimus (RAD001)
8 Recruiting A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
Condition: Malignant Peripheral Nerve Sheath Tumour (MPNST)
Intervention: Drug: Pembrolizumab
9 Completed Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
Conditions: Neurofibromatosis Type 1;   Cutaneous Neurofibromas
Intervention: Drug: Ranibizumab
10 Completed Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
Conditions: Neurofibromas;   Neurofibromatosis Type 1
Intervention:
11 Completed Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
Conditions: Neurofibromatosis Type 1;   Cutaneous Neurofibromas
Intervention: Drug: Imiquimod 5% Cream
12 Completed
Has Results
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
Conditions: Neurofibroma, Plexiform;   Neurofibromatosis Type I
Interventions: Drug: tipifarnib;   Other: placebo
13 Completed Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
Conditions: Neurofibromatosis Type I;   Plexiform Neurofibroma
Interventions: Drug: Nexavar (BAY 43-9006) (Sorafenib);   Drug: Toxicity, Pharmacokinetics;   Drug: Pharmacodynamics;   Drug: Radiographic Evaluation;   Drug: QOL assessment, Neuropsychological;   Drug: Bony Toxicity
14 Completed
Has Results
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Conditions: Neurofibromatosis 1;   Neurofibroma, Plexiform
Intervention: Drug: Pirfenidone
15 Active, not recruiting Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Conditions: Neurofibromatosis;   NF1;   Neurofibromas
Intervention: Drug: Tasigna
16 Recruiting Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Selumetinib
17 Recruiting Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
Conditions: Neurofibromatosis 1;   Plexiform Neurofibromas
Intervention:
18 Recruiting Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Conditions: Cutaneous Neurofibromas;   Neurofibromatosis Type 1;   Plexiform Neurofibromas
Intervention: Procedure: Skin Biopsy
19 Suspended
Has Results
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
Conditions: Neurofibromatosis;   NF1;   Plexiform Neurofibromas
Intervention: Drug: Sutent®/Sunitinib
20 Active, not recruiting
Has Results
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma;   Spinal Cord Neurofibroma
Intervention: Drug: Cediranib Maleate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.